Cannara BiotechLOVFF +5.52%83 Pretax Margin % is 10.37% as of Feb. 2026, which is 89% above its 10-year median of 5.49. GuruFocus rates LOVFF with a GF Score™ of 83/100 and a GF Value™ of $1.15 (Fairly Valued). The stock has 4 warning signs investors should review. Among 952 Drug Manufacturers companies, Cannara Biotech ranks better than 66.07% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Cannara Biotech Pretax Margin % Related Terms
Cannara Biotech Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Cannara Biotech's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannara Biotech Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Cannara Biotech's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannara Biotech (LOVFF) has a Pretax Margin % of 10.37% as of Feb. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Cannara Biotech and its competitors. This is 89% above median its historical median of 5.49. According to the industry distribution chart, Cannara Biotech ranks #323 out of 952 companies in the Drug Manufacturers industry, placing it in the top 33.9%.
Is Cannara Biotech's Pretax Margin % too high?
Cannara Biotech's current Pretax Margin % of 10.37% is 89% above median its 10-year median of 5.49. The Drug Manufacturers industry median Pretax Margin % is 7.30. Cannara Biotech's value of 10.37% is 42.2% above this industry median. Based on the distribution chart, Cannara Biotech ranks #323 out of 952 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cannara Biotech has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cannara Biotech ranks #323 out of 952 companies for Pretax Margin %. This puts Cannara Biotech in the upper half of its industry. The industry median Pretax Margin % is 7.30. Cannara Biotech's value of 10.37% is 42.2% above this benchmark. While the company's 10-year median is 5.49 vs. the industry median of 7.30, Cannara Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannara Biotech's current Pretax Margin % of 10.37% is 42.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Cannara Biotech and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannara Biotech's current Pretax Margin % is 10.37%, which is 89% above median its own 10-year median of 5.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Fairly Valued. The stock's GF Value™ is $1.15, compared to a current price of $1.21 — trading 5.5% above its estimated fair value. The current Pretax Margin % is 10.37%, which is 89% above median its 10-year median of 5.49 and 42.2% above the Drug Manufacturers industry median of 7.30. Cannara Biotech's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current Pretax Margin % is 10.37% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cannara Biotech (LOVFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued.
The current stock price of $1.21 is trading 5.5% above its estimated GF Value™ of $1.15.
GuruFocus considers Cannara Biotech to be Fairly Valued.
Key valuation signals for LOVFF:
Pretax Margin %: 10.37% (89% above median its 10-year median of 5.49)
GF Value™: $1.15 vs. price of $1.21 (5.5% above fair value)
Industry Position: 42.2% above the Drug Manufacturers median (#323 of 952)
No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
83GF Score
Get the complete analysis for LOVFF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LOVFF has been successfully added to your 
